Connect Biopharma Holdings Limited (CNTB) vs INmune Bio, Inc. (INMB)
A side-by-side comparison of Connect Biopharma Holdings Limited and INmune Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CNTB
Connect Biopharma Holdings Limited
$0.89HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
INMB
INmune Bio, Inc.
$1.93HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
Total return — CNTB vs INMB
growth of $100 · dividends reinvested · last 6yCNTB -95.1% (-39.6%/yr)INMB -86.5% (-28.4%/yr)INMB compounded faster over this window
CNTB INMB
CNTB vs INMB: by the numbers
- •CNTB is the larger company ($56M vs $51M market cap).
- •Both run net losses; CNTB's is the smaller (-86687.50% vs -91866.00% net margin).
Metrics side by side
Valuation
| Metric | CNTB | INMB |
|---|---|---|
| P/B ratio | 2.09 | 2.52 |
Profitability
| Metric | CNTB | INMB |
|---|---|---|
| Gross margin | 100.00% | 100.00% |
| Operating margin | -90740.62% | -61738.00% |
| Net margin | -86687.50% | -91866.00% |
| ROE | -132.16% | -90.44% |
| ROIC | -136.77% | -96.37% |
Growth (annualized)
| Metric | CNTB | INMB |
|---|---|---|
| Total return CAGR (5Y) | -47.22% | -36.88% |
Frequently asked
- How have CNTB and INMB total returns compared?
- Over the past 5 years, CNTB delivered -47.22% and INMB delivered -36.88% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.